Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P131 (ribosomal protein L21 pseudogene 131) is a processed pseudogene derived from the ribosomal protein L21 gene (RPL21). While its sequence resembles the functional ribosomal protein L21 gene, RPL21P131 has accumulated mutations such that it cannot produce a functional protein. Pseudogenes like RPL21P131 are common in the human genome and typically do not perform biological roles nor serve as drug targets[2][8]. The functional ribosomal protein L21 (encoded by RPL21) is a protein component of the large (60S) ribosomal subunit, which participates in protein synthesis[3][5], but RPL21P131 itself does not encode a protein or participate in ribosome function or cellular pathways. RPL21P131 is not a therapeutic target, receptor, enzyme, transporter, or functional gene. The query may be incorrect if the intent was to identify a druggable protein or biomarker, as RPL21P131 is a pseudogene with no established function or clinical relevance.
None; pseudogenes are not targeted by drugs for a mechanism of action
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 131 (RPL21P131).